Nisa Investment Advisors LLC lowered its position in Insmed Incorporated (NASDAQ:INSM – Get Rating) by 21.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,905 shares of the biopharmaceutical company’s stock after selling 810 shares during the period. Nisa Investment Advisors LLC’s holdings in Insmed were worth $68,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also recently added to or reduced their stakes in INSM. Assenagon Asset Management S.A. lifted its position in Insmed by 8,961.3% in the first quarter. Assenagon Asset Management S.A. now owns 803,734 shares of the biopharmaceutical company’s stock valued at $18,888,000 after purchasing an additional 794,864 shares during the period. Alliancebernstein L.P. lifted its position in Insmed by 27.2% in the fourth quarter. Alliancebernstein L.P. now owns 2,819,013 shares of the biopharmaceutical company’s stock valued at $76,790,000 after purchasing an additional 603,211 shares during the period. Dimensional Fund Advisors LP lifted its position in Insmed by 254.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 409,216 shares of the biopharmaceutical company’s stock valued at $11,147,000 after purchasing an additional 293,890 shares during the period. Alps Advisors Inc. acquired a new stake in Insmed in the fourth quarter valued at about $3,732,000. Finally, Bellevue Group AG lifted its position in Insmed by 4.0% in the fourth quarter. Bellevue Group AG now owns 3,520,861 shares of the biopharmaceutical company’s stock valued at $95,908,000 after purchasing an additional 135,216 shares during the period.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on INSM shares. The Goldman Sachs Group reduced their price objective on shares of Insmed from $56.00 to $48.00 and set a “buy” rating for the company in a research report on Tuesday, May 24th. Morgan Stanley dropped their target price on shares of Insmed from $46.00 to $41.00 and set an “overweight” rating for the company in a report on Friday, July 15th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $49.67.
Insider Transactions at Insmed
Insmed Trading Down 1.8 %
Shares of Insmed stock opened at $22.12 on Friday. The company has a current ratio of 6.04, a quick ratio of 5.52 and a debt-to-equity ratio of 6.73. The company has a 50-day moving average of $20.63 and a two-hundred day moving average of $21.98. Insmed Incorporated has a 12-month low of $16.41 and a 12-month high of $34.44. The stock has a market cap of $2.64 billion, a PE ratio of -5.85 and a beta of 1.93.
Insmed (NASDAQ:INSM – Get Rating) last issued its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.11. Insmed had a negative net margin of 217.35% and a negative return on equity of 108.20%. The business had revenue of $53.10 million during the quarter, compared to analysts’ expectations of $53.36 million. During the same period last year, the company posted ($0.89) EPS. The company’s revenue was up 32.1% on a year-over-year basis. On average, research analysts anticipate that Insmed Incorporated will post -3.52 EPS for the current fiscal year.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
- Get a free copy of the StockNews.com research report on Insmed (INSM)
- Procter’s Earnings Start To Show Weakness In Q4
- MarketBeat: Week in Review 7/25 – 7/29
- The One Question You Have to Ask Before Investing in INTC Stock
- Home Depot: A Beautiful Boring Stock to Navigate a Bear Market
- Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.